SynthesisArchives of dermatological research2019
Small intestinal bacterial overgrowth in systemic sclerosis: a review of the literature.
Synthesis in Archives of dermatological research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07652827 (Efficacy of a Probiotic Formulation), which is not on this map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy of a Probiotic Formulation (Lacticaseibacillus Rhamnosus - Limosilactobacillus Fermentum) on Gastrointestinal Symptoms in Adults With Lactose Intolerance and Methanogenic Intestinal Overgrowth
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Prevalence and predictors of small intestinal bacterial overgrowth in systemic sclerosis: a systematic review and meta-analysis.Clinical rheumatology · 2021Pooled it
- Obesity and Risk of Small Intestine Bacterial Overgrowth: A Systematic Review and Meta-Analysis.Digestive diseases and sciences · 2020Pooled it
- Unraveling the Complexities of Small Intestinal Bacterial Overgrowth.Medicina (Kaunas, Lithuania) · 2026Review
- Severe scleroderma colopathy at initial diagnosis of systemic sclerosis in a young man: a case report.Frontiers in medicine · 2026Article
- [S2k guidelines on diagnostics and treatment of systemic sclerosis : Full version].Zeitschrift fur Rheumatologie · 2025Review
- Eradication of Small Intestinal Bacterial Overgrowth in Systemic Sclerosis: Current Treatment and Perspectives-A Narrative Review.Biomedicines · 2025Review
- Modern concepts of small intestinal bacterial overgrowth.Current opinion in gastroenterology · 2025Review
- Plasma Dephosphorylated-Uncarboxylated Matrix Gla-Protein in Systemic Sclerosis Patients: Biomarker Potential for Vascular Calcification and Inflammation.Diagnostics (Basel, Switzerland) · 2023Article
- Clinical Presentation of Small Intestinal Bacterial Overgrowth from Aerodigestive Tract Bacteria Versus Colonic-Type Bacteria: A Comparison Study.Digestive diseases and sciences · 2023Article
- Epidemiology of small intestinal bacterial overgrowth.World journal of gastroenterology · 2023Review
- Aetiology, diagnosis and management of small intestinal bacterial overgrowth.Frontline gastroenterology · 2023Article
- The Involvement of Smooth Muscle, Striated Muscle, and the Myocardium in Scleroderma: A Review.International journal of molecular sciences · 2022Review
- Asian-Pacific consensus on small intestinal bacterial overgrowth in gastrointestinal disorders: An initiative of the Indian Neurogastroenterology and Motility Association.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2022Article
- The Relationship between Gastrointestinal Health, Micronutrient Concentrations, and Autoimmunity: A Focus on the Thyroid.Nutrients · 2022Review
- Management of scleroderma gastrointestinal disease: Lights and shadows.Journal of scleroderma and related disorders · 2022Review
- Systemic Scleroderma-Definition, Clinical Picture and Laboratory Diagnostics.Journal of clinical medicine · 2022Review
- Paul Klee's gastrointestinal maladies: A series of historical and clinical vignettes, part IV.Journal of scleroderma and related disorders · 2022Article
- Diet in Scleroderma: Is There a Need for Intervention?Diagnostics (Basel, Switzerland) · 2021Article
- Fecal microbiome differs between patients with systemic sclerosis with and without small intestinal bacterial overgrowth.Journal of scleroderma and related disorders · 2021Article
- A practical approach to the evaluation and management of gastrointestinal symptoms in patients with systemic sclerosis.Best practice & research. Clinical rheumatology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic sclerosis (SSc) is a chronic, connective tissue disease with an autoimmune pattern characterized by inflammation, fibrosis and microcirculation changes leading to internal organs malfunctions. Recently, the presence of uncharacteristic gastrointestinal symptoms in the course of SSc has been underlined. The possible cause of such clinical presentation is the small intestinal bacterial overgrowth (SIBO). Nevertheless, these manifestations resulting from gastrointestinal tract hypomotility may occur in numerous disease entities. The systematic review of the literature was performed on MEDLINE database using the relevant MeSH terms including all sub-headings. After further investigation, the initial number of 56 records was limited to 7 results. The study analysis showed an increased presence of SIBO in 39% of patients suffering from SSc. The average SSc duration was longer in SSc patients with coexisting SIBO. SIBO remains a diagnostic and therapeutic challenge and therefore is a significant clinical problem among patients suffering from SSc.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.